Plasma metabolites in patients of the REDINSCOR III registry hospitalised for de novo heart failure with preserved ejection fraction: Prognostic implications of linoleamide and 2-trans,4-cisdecadienoylcarnitine levels

Marta Delgado-Arija; M Dolores García-Cosío Carmena; Manuel Martínez-Sellés; José M Guerra; Sandra Valdivielso; José R González-Juanatey; Mercedes Rivas-Lasarte; Esther Roselló-Lletí; Julián Pérez-Villacastín; Anna Carrasquer; Lucía Matute-Blanco; Antonio Grande-Trillo; Maria Generosa Crespo-Leiro; Juan F Delgado; Luis Martínez-Dolz

doi:10.1002/ctm2.70398

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (9) : e70398 DOI: 10.1002/ctm2.70398

LETTER TO THE JOURNAL

Plasma metabolites in patients of the REDINSCOR III registry hospitalised for de novo heart failure with preserved ejection fraction: Prognostic implications of linoleamide and 2-trans,4-cisdecadienoylcarnitine levels

Author information +

¹. Clinical and Translational Research in Cardiology Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain

². Center for Biomedical Research Network on Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain

³. Cardiology Department, Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain

⁴. Cardiology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Europea, Universidad Complutense, Madrid, Spain

⁵. Cardiology Department, Hospital de la Santa Creu i Sant Pau, IR SANT PAU, Universitat Autònoma de Barcelona, Barcelona, Spain

⁶. Cardiology Department, Hospital del Mar, Hospital del Mar Research Institute, Barcelona, Spain

⁷. Cardiology Department, University Hospital, IDIS, Santiago de Compostela, Spain

⁸. Cardiology Department, Unidad de Insuficiencia Cardiaca Avanzada, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain

⁹. Cardiology Department, Hospital Clínico San Carlos, Madrid, Spain

¹⁰. Cardiology Department, Hospital Universitario Joan XXIII de Tarragona (Spain), IISPV, Universidad Rovira Virgili, Tarragona, Spain

¹¹. Cardiology Department, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut. IRBLleida, Lleida, Spain

¹². Cardiology Department, Unidad de IC avanzada y Trasplante Cardíaco, Hospital Universitario Virgen del Rocío, Sevilla, Spain

¹³. Department of Cardiology, Complexo Hospitalario Universitario a Coruña (CHUAC), Instituto de Investigación Biomédica a Coruña (INIBIC), Universidad de A Coruña (UDC), A Coruña, Spain

¹⁴. Heart Failure and Transplantation Unit, Cardiology Department, University and Polytechnic La Fe Hospital, Valencia, Spain

esther_rosello@iislafe.es

Show less

History +

PDF

Cite this article

Download citation ▾

Marta Delgado-Arija, M Dolores García-Cosío Carmena, Manuel Martínez-Sellés, José M Guerra, Sandra Valdivielso, José R González-Juanatey, Mercedes Rivas-Lasarte, Esther Roselló-Lletí, Julián Pérez-Villacastín, Anna Carrasquer, Lucía Matute-Blanco, Antonio Grande-Trillo, Maria Generosa Crespo-Leiro, Juan F Delgado, Luis Martínez-Dolz. Plasma metabolites in patients of the REDINSCOR III registry hospitalised for de novo heart failure with preserved ejection fraction: Prognostic implications of linoleamide and 2-trans,4-cisdecadienoylcarnitine levels. Clinical and Translational Medicine, 2025, 15(9): e70398 DOI:10.1002/ctm2.70398

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Campbell P, Rutten FH, Lee MM, Hawkins NM, Petrie MC. Heart failure with preserved ejection fraction: everything the clinician needs to know. Lancet. 2024; 403(10431): 1026.

[2]	Huang JK, Jan CR. Linoleamide, a brain lipid that induces sleep, increases cytosolic Ca2+ levels in MDCK renal tubular cells. Life Sci. 2001; 68(9): 997-1004.

[3]	Yamamoto S, Takehara M, Ushimaru M. Inhibitory action of linoleamide and oleamide toward sarco/endoplasmic reticulum Ca²⁺-ATPase. Biochim Biophys Acta Gen Subj. 2017; 1861(1): 3399-3405. Pt A.

[4]	Tarazón E, Gil-Cayuela C, Manzanares MG, et al. Circulating Sphingosine-1-phosphate as a non-invasive biomarker of heart transplant rejection. Sci Rep. 2019; 9(1): 13880.

[5]	Pérez-Carrillo L, Giménez-Escamilla I, Martínez-Dolz L, et al. Implication of sphingolipid metabolism gene dysregulation and cardiac Sphingosine-1-phosphate accumulation in heart failure. Biomedicines. 2022; 10(1): 135.

[6]	Kumar AA, Kelly DP, Chirinos JA. Mitochondrial dysfunction in heart failure with preserved ejection fraction. Circulation. 2019; 139(11): 1435-1450.

[7]

Hunter WG, Kelly JP. Metabolomic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction: evidence for shared metabolic impairments in clinical heart failure. J Am Heart Assoc. 2016; 5(8): e003190.

[8]	Liu G, Nguyen NQH, Wong KE, et al. Metabolomic association and risk prediction with heart failure in older adults. Circ Heart Fail. 2024; 17(3): e010896.

[9]	Ruiz-Canela M, Guasch-Ferré M, Razquin C, et al. Plasma acylcarnitines and risk of incident heart failure and atrial fibrillation: the Prevención con dieta mediterránea study. Rev Esp Cardiol (Engl Ed). 2022; 75(8): 649-658.

[10]	Zhang R, Zhang K. Mitochondrial NAD kinase in health and disease. Redox Biol. 2023; 60: 102613.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.